α-Synuclein and dopamine at the crossroads of Parkinson's disease

Trends in Neurosciences

Volumn 33, Issue 12, 2010, Pages 559-568

  Venda, Lara Lourenço ^a,b   Cragg, Stephanie J ^a,b   Buchman, Vladimir L ^c   Wade Martins, Richard ^a,b  

^a Department of Physiology Anatomy and Genetics ^*  (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; DOPAMINE; MICRORNA;

ALTERNATIVE RNA SPLICING; DOPAMINE METABOLISM; DOPAMINE RELEASE; DOPAMINE UPTAKE; DOPAMINERGIC NERVE CELL; NERVE DEGENERATION; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SYNAPSE VESICLE; SYNAPTIC TRANSMISSION;

ALPHA-SYNUCLEIN; ALTERNATIVE SPLICING; ANIMALS; DOPAMINE; HUMANS; MICRORNAS; NEURONS; PARKINSON DISEASE; SYNAPTIC VESICLES;

EID: 78149466909     PISSN: 01662236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tins.2010.09.004     Document Type: Review

References (108)

1. Samii A., et al. Parkinson's disease. Lancet 2004, 363:1783-1793.
2. Spillantini M.G., et al. Alpha-synuclein in Lewy bodies. Nature 1997, 388:839-840.
3. Dickson D.W., et al. Neuropathology of non-motor features of Parkinson disease. Parkinsonism Relat. Disord. 2009, 15(Suppl. 3):S1-5.
4. Wolters E. Non-motor extranigral signs and symptoms in Parkinson's disease. Parkinsonism Relat. Disord. 2009, 15(Suppl. 3):S6-12.
5. Gasser T. Molecular pathogenesis of Parkinson disease: insights from genetic studies. Expert Rev. Mol. Med. 2009, 11:e22.
6. Di Monte D.A. The environment and Parkinson's disease: is the nigrostriatal system preferentially targeted by neurotoxins?. Lancet Neurol. 2003, 2:531-538.
7. Sulzer D. Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease. Trends Neurosci. 2007, 30:244-250.
8. Polymeropoulos M.H., et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997, 276:2045-2047.
9. Krüger R., et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 1998, 18:106-108.
10. Zarranz J.J., et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 2004, 55:164-173.
11. Singleton A.B., et al. alpha-Synuclein locus triplication causes Parkinson's disease. Science 2003, 302:841.
12. Chartier-Harlin M.C., et al. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 2004, 364:1167-1169.
13. Ibanez P., et al. Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet 2004, 364:1169-1171.
14. Farrer M., et al. Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. Ann. Neurol. 2004, 55:174-179.
15. Miller D.W., et al. Alpha-synuclein in blood and brain from familial Parkinson disease with SNCA locus triplication. Neurology 2004, 62:1835-1838.
16. Simon-Sanchez J., et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat. Genet. 2009, 41:1308-1312.
17. Satake W., et al. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat. Genet. 2009, 41:1303-1307.
18. Farrer M., et al. alpha-Synuclein gene haplotypes are associated with Parkinson's disease. Hum. Mol. Genet. 2001, 10:1847-1851.
19. Maraganore D.M., et al. Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease. J. Am. Med. Assoc. 2006, 296:661-670.
20. Edwards T.L., et al. Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease. Ann. Hum. Genet. 2010, 74:97-109.
21. Gandhi S., Wood N.W. Genome-wide association studies: the key to unlocking neurodegeneration?. Nat. Neurosci. 2010, 13:789-794.
22. Xia Y., et al. Genetic studies in Alzheimer's disease with an NACP/alpha-synuclein polymorphism. Ann. Neurol. 1996, 40:207-215.
23. Touchman J.W., et al. Human and mouse alpha-synuclein genes: comparative genomic sequence analysis and identification of a novel gene regulatory element. Genome Res. 2001, 11:78-86.
24. Pals P., et al. alpha-Synuclein promoter confers susceptibility to Parkinson's disease. Ann. Neurol. 2004, 56:591-595.
25. Chiba-Falek O., Nussbaum R.L. Effect of allelic variation at the NACP-Rep1 repeat upstream of the alpha-synuclein gene (SNCA) on transcription in a cell culture luciferase reporter system. Hum. Mol. Genet. 2001, 10:3101-3109.
26. Cronin K.D., et al. Expansion of the Parkinson disease-associated SNCA-Rep1 allele upregulates human alpha-synuclein in transgenic mouse brain. Hum. Mol. Genet. 2009, 18:3274-3285.
27. Chiba-Falek O., et al. Levels of alpha-synuclein mRNA in sporadic Parkinson disease patients. Mov. Disord. 2006, 21:1703-1708.
28. Dachsel J.C., et al. The ups and downs of alpha-synuclein mRNA expression. Mov. Disord. 2007, 22:293-295.
29. Kingsbury A.E., et al. Alteration in alpha-synuclein mRNA expression in Parkinson's disease. Mov. Disord. 2004, 19:162-170.
30. Beyer K. Alpha-synuclein structure, posttranslational modification and alternative splicing as aggregation enhancers. Acta Neuropathol. 2006, 112:237-251.
31. Kalivendi S.V., et al. Oxidants induce alternative splicing of alpha-synuclein: implications for Parkinson's disease. Free Radic. Biol. Med. 2010, 48:377-383.
32. Junn E., et al. Repression of alpha-synuclein expression and toxicity by microRNA-7. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:13052-13057.
33. Doxakis E. Post-transcriptional regulation of alpha-synuclein expression by mir-7 and mir-153. J. Biol. Chem. 2010, 285:12726-12734.
34. Fuchs J., et al. Genetic variability in the SNCA gene influences alpha-synuclein levels in the blood and brain. FASEB J. 2008, 22:1327-1334.
35. Perez R.G., et al. A role for alpha-synuclein in the regulation of dopamine biosynthesis. J. Neurosci. 2002, 22:3090-3099.
36. Liu D., et al. Silencing alpha-synuclein gene expression enhances tyrosine hydroxylase activity in MN9D cells. Neurochem. Res. 2008, 33:1401-1409.
37. Gao N., et al. Effect of alpha-synuclein on the promoter activity of tyrosine hydroxylase gene. Neurosci. Bull. 2007, 23:53-57.
38. Baptista M.J., et al. Coordinate transcriptional regulation of dopamine synthesis genes by alpha-synuclein in human neuroblastoma cell lines. J. Neurochem. 2003, 85:957-968.
39. Yu S., et al. Inhibition of tyrosine hydroxylase expression in alpha-synuclein-transfected dopaminergic neuronal cells. Neurosci. Lett. 2004, 367:34-39.
40. Peng X., et al. Alpha-synuclein activation of protein phosphatase 2A reduces tyrosine hydroxylase phosphorylation in dopaminergic cells. J. Cell Sci. 2005, 118:3523-3530.
41. Masliah E., et al. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 2000, 287:1265-1269.
42. Kirik D., et al. Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. J. Neurosci. 2002, 22:2780-2791.
43. Tehranian R., et al. Alpha-synuclein inhibits aromatic amino acid decarboxylase activity in dopaminergic cells. J. Neurochem. 2006, 99:1188-1196.
44. Abeliovich A., et al. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 2000, 25:239-252.
45. Robertson D.C., et al. Developmental loss and resistance to MPTP toxicity of dopaminergic neurones in substantia nigra pars compacta of gamma-synuclein, alpha-synuclein and double alpha/gamma-synuclein null mutant mice. J. Neurochem. 2004, 89:1126-1136.
46. Schlüter O.M., et al. Role of alpha-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice. Neuroscience 2003, 118:985-1002.
47. Alerte T.N., et al. Alpha-synuclein aggregation alters tyrosine hydroxylase phosphorylation and immunoreactivity: lessons from viral transduction of knockout mice. Neurosci. Lett. 2008, 435:24-29.
48. Al-Wandi A., et al. Absence of alpha-synuclein affects dopamine metabolism and synaptic markers in the striatum of aging mice. Neurobiol. Aging 2008, 31:796-804.
49. Cabin D.E., et al. Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. J. Neurosci. 2002, 22:8797-8807.
50. Murphy D.D., et al. Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J. Neurosci. 2000, 20:3214-3220.
51. Nemani V.M., et al. Increased expression of α-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron 2010, 65:66-79.
52. Yavich L., et al. Role of alpha-synuclein in presynaptic dopamine recruitment. J. Neurosci. 2004, 24:11165-11170.
53. Senior S.L., et al. Increased striatal dopamine release and hyperdopaminergic-like behaviour in mice lacking both alpha-synuclein and gamma-synuclein. Eur. J. Neurosci. 2008, 27:947-957.
54. Buchman V.L., Ninkina N. Modulation of alpha-synuclein expression in transgenic animals for modelling synucleinopathies - is the juice worth the squeeze?. Neurotox. Res. 2008, 14:329-341.
55. Gorbatyuk O.S., et al. In vivo RNAi-mediated alpha-synuclein silencing induces nigrostriatal degeneration. Mol. Ther. 2010, 18:1450-1457.
56. Yavich L., et al. Locomotor activity and evoked dopamine release are reduced in mice overexpressing A30P-mutated human alpha-synuclein. Neurobiol. Dis. 2005, 20:303-313.
57. Larsen K.E., et al. Alpha-synuclein overexpression in PC12 and chromaffin cells impairs catecholamine release by interfering with a late step in exocytosis. J. Neurosci. 2006, 26:11915-11922.
58. Gitler A.D., et al. The Parkinson's disease protein alpha-synuclein disrupts cellular Rab homeostasis. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:145-150.
59. Cooper A.A., et al. Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science 2006, 313:324-328.
60. Chandra S., et al. Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. Cell 2005, 123:383-396.
61. Fountaine T.M., Wade-Martins R. RNA interference-mediated knockdown of alpha-synuclein protects human dopaminergic neuroblastoma cells from MPP(+) toxicity and reduces dopamine transport. J. Neurosci. Res. 2007, 85:351-363.
62. Fountaine T.M., et al. The effect of alpha-synuclein knockdown on MPP+ toxicity in models of human neurons. Eur. J. Neurosci. 2008, 28:2459-2473.
63. Wersinger C., Sidhu A. Attenuation of dopamine transporter activity by alpha-synuclein. Neurosci. Lett. 2003, 340:189-192.
64. Lee F.J., et al. Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. FASEB J. 2001, 15:916-926.
65. Gosavi N., et al. Golgi fragmentation occurs in the cells with prefibrillar alpha-synuclein aggregates and precedes the formation of fibrillar inclusion. J. Biol. Chem. 2002, 277:48984-48992.
66. Dauer W., et al. Resistance of alpha-synuclein null mice to the parkinsonian neurotoxin MPTP. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:14524-14529.
67. Matsuda W., et al. Single nigrostriatal dopaminergic neurons form widely spread and highly dense axonal arborizations in the neostriatum. J. Neurosci. 2009, 29:444-453.
68. Oorschot D.E. Total number of neurons in the neostriatal, pallidal, subthalamic, and substantia nigral nuclei of the rat basal ganglia: a stereological study using the cavalieri and optical disector methods. J. Comp. Neurol. 1996, 366:580-599.
69. Arbuthnott G.W., Wickens J. Space, time and dopamine. Trends Neurosci. 2007, 30:62-69.
70. Bender A., et al. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat. Genet. 2006, 38:515-517.
71. Kraytsberg Y., et al. Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neurons. Nat. Genet. 2006, 38:518-520.
72. Fornstedt B., Carlsson A. A marked rise in 5-S-cysteinyl-dopamine levels in guinea-pig striatum following reserpine treatment. J. Neural Transm. 1989, 76:155-161.
73. Fearnley J.M., Lees A.J. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991, 114:2283-2301.
74. Damier P., et al. The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28K) immunohistochemistry. Brain 1999, 122:1421-1436.
75. Kish S.J., et al. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N. Engl. J. Med. 1988, 318:876-880.
76. Chung C.Y., et al. Cell type-specific gene expression of midbrain dopaminergic neurons reveals molecules involved in their vulnerability and protection. Hum. Mol. Genet. 2005, 14:1709-1725.
77. Mendez I., et al. Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson's disease. Brain 2005, 128:1498-1510.
78. Chan C.S., et al. 'Rejuvenation' protects neurons in mouse models of Parkinson's disease. Nature 2007, 447:1081-1086.
79. Surmeier D.J. Calcium, ageing, and neuronal vulnerability in Parkinson's disease. Lancet Neurol. 2007, 6:933-938.
80. Liss B., et al. K-ATP channels promote the differential degeneration of dopaminergic midbrain neurons. Nat. Neurosci. 2005, 8:1742-1751.
81. Liss B., et al. The weaver mouse gain-of-function phenotype of dopaminergic midbrain neurons is determined by coactivation of wvGirk2 and K-ATP channels. J. Neurosci. 1999, 19:8839-8848.
82. Miller G.W., et al. Dopamine transporters and neuronal injury. Trends Pharmacol. Sci. 1999, 20:424-429.
83. Uhl G.R. Hypothesis: the role of dopaminergic transporters in selective vulnerability of cells in Parkinson's disease. Ann. Neurol. 1998, 43:555-560.
84. Richardson J.R., et al. Developmental exposure to the pesticide dieldrin alters the dopamine system and increases neurotoxicity in an animal model of Parkinson's disease. FASEB J. 2006, 20:1695-1697.
85. Wolfart J., et al. Differential expression of the small-conductance, calcium-activated potassium channel SK3 is critical for pacemaker control in dopaminergic midbrain neurons. J. Neurosci. 2001, 21:3443-3456.
86. Neuhoff H., et al. I(h) channels contribute to the different functional properties of identified dopaminergic subpopulations in the midbrain. J. Neurosci. 2002, 22:1290-1302.
87. Cragg S.J. Variable dopamine release probability and short-term plasticity between functional domains of the primate striatum. J. Neurosci. 2003, 23:4378-4385.
88. Exley R., et al. Alpha6-containing nicotinic acetylcholine receptors dominate the nicotine control of dopamine neurotransmission in nucleus accumbens. Neuropsychopharmacology 2008, 33:2158-2166.
89. Threlfell S., et al. Striatal muscarinic receptors promote activity dependence of dopamine transmission via distinct receptor subtypes on cholinergic interneurons in ventral versus dorsal striatum. J. Neurosci. 2010, 30:3398-3408.
90. Mosharov E.V., et al. Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons. Neuron 2009, 62:218-229.
91. Conway K.A., et al. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 2001, 294:1346-1349.
92. Volles M.J., Lansbury P.T. Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease. Biochemistry 2003, 42:7871-7878.
93. Jenner P. Oxidative stress in Parkinson's disease. Ann. Neurol. 2003, 53:S26-S36.
94. Davidson W.S., et al. Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J. Biol. Chem. 1998, 273:9443-9449.
95. Giasson B.I., et al. A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly. J. Biol. Chem. 2001, 276:2380-2386.
96. Conway K.A., et al. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:571-576.
97. Dev K.K., et al. Part II: alpha-synuclein and its molecular pathophysiological role in neurodegenerative disease. Neuropharmacology 2003, 45:14-44.
98. Caughey B., Lansbury P.T. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu. Rev. Neurosci. 2003, 26:267-298.
99. Sharon R., et al. The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson's disease. Neuron 2003, 37:583-595.
100. Hashimoto M., et al. Oxidative stress induces amyloid-like aggregate formation of NACP/alpha-synuclein in vitro. Neuroreport 1999, 10:717-721.
101. Hashimoto M., et al. Role of cytochrome c as a stimulator of alpha-synuclein aggregation in Lewy body disease. J. Biol. Chem. 1999, 274:28849-28852.
102. Giasson B.I., et al. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 2000, 290:985-989.
103. Uversky V.N. Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation. J. Neurochem. 2007, 103:17-37.
104. Crowther R.A., et al. Synthetic filaments assembled from C-terminally truncated alpha-synuclein. FEBS Lett. 1998, 436:309-312.
105. Murray I.V., et al. Role of alpha-synuclein carboxy-terminus on fibril formation in vitro. Biochemistry 2003, 42:8530-8540.
106. Baba M., et al. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am. J. Pathol. 1998, 152:879-884.
107. Anderson J.P., et al. Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J. Biol. Chem. 2006, 281:29739-29752.
108. Wakamatsu M., et al. Selective loss of nigral dopamine neurons induced by overexpression of truncated human alpha-synuclein in mice. Neurobiol. Aging 2008, 29:574-585.